Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on December 9, 2008
JNCI Journal of the National Cancer Institute 2008 100(24):1745-1747; doi:10.1093/jnci/djn433
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
100/24/1745    most recent
djn433v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Bedard, P. L.
Right arrow Articles by Piccart-Gebhart, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bedard, P. L.
Right arrow Articles by Piccart-Gebhart, M. J.
Related Collections
Right arrowRelated Articles in JNCI
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press.

EDITORIALS

Nonhormonal Systemic Therapy for Advanced Breast Cancer: Do the Math!

Philippe L. Bedard, Martine J. Piccart-Gebhart

Affiliations of authors: Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium (PLB, MJP-G); Université Libre de Bruxelles, Brussels, Belgium (MJP-G)

Correspondence to: Martine J. Piccart-Gebhart, Head of Medicine Department, Jules Bordet Institute, Rue Heger-Bordet 1, 1000 Brussels, Belgium (e-mail: martine.piccart@bordet.be).

The first 10% of the full text of this article appears below.

Since the founding of the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) 25 years ago (1), early breast cancer trials encompassing all aspects of operable breast cancer management have been compiled to produce individual patient data meta-analyses at 5-year intervals. The EBCTCG overviews have quantified the impact of adjuvant polychemotherapy, tamoxifen, ovarian suppression/ablation, and radiation on overall survival (OS) and disease-related events (2), informing widely used evidence-based clinical practice guidelines (3,4) and contributing to the ongoing decline of breast cancer–related mortality in Western societies (5). The most recent cycle of the EBCTCG overview includes data from more than 661,000 patients with early breast cancer who were randomly assigned across 823 clinical trials (5).

. . . [Full Text of this Article]

Funding


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Articles in JNCI

IN THIS ISSUE
J Natl Cancer Inst 2008 100: 1741. [Extract] [Full Text] [PDF]

Nonhormonal Treatment Regimens Substantially Improve Overall Survival in Patients with Metastatic Breast Cancer
J Natl Cancer Inst 2008 100: 1741. [Extract] [Full Text] [PDF]